Erschienen in:
06.09.2022 | ASO Author Reflections
ASO Author Reflections: Evaluating HIPEC Switch for Repeat CRS–HIPEC, Time to End a Common Practice?
verfasst von:
Christopher W. Mangieri, MD, Edward A. Levine, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Excerpt
As cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS–HIPEC) has progressed from an investigative procedure to an accepted oncologic technique, the standards for CRS–HIPEC have also shifted from anecdotal expert experience to objective evidence-based practice. The most relevant example of that formal guidance is the publication of the Chicago Consensus guidelines, which the majority of leading peritoneal surface malignancy (PSM) centers follow.
1 Current practice, as well as the Chicago Consensus, advocates for repeat CRS–HIPEC at experienced PSM centers for well-selected patients. A common practice with iterative CRS–HIPEC is to switch the HIPEC perfusion agent utilized at the index surgery. However, that commonly performed HIPEC approach is based more on theory than on science. There have only been two previous publications addressing the effectiveness of HIPEC switch at repeat surgery, with mixed conclusions.
2,3 …
